Data Sheet (Cat.No.T6401)



Azithromycin

Chemical Properties


CAS No.: 83905-01-5

Formula: C38H72N2O12

Molecular Weight: 748.98

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	Azithromycin (CP 62993) is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections.
Targets(IC50)	Antibacterial, Antibiotic, Autophagy
In vitro	Azithromycin reduces about 40% of IL-8 mRNA and protein expression in cystic fibrosis (CF) cells reaching the levels of non-CF cells. Azithromycin results in 50% and 70% reduction of NF-kappaB and AP-1 DNA binding, respectively, leading to levels of non-CF cells. Azithromycin significantly enhances the intensity of a co-stimulatory molecule, CD80, on DCs but not CD86 and CD40 in dendritic cells (DCs). Azithromycin significantly increases the production of IL-10 and Clarithromycin (CAM) significantly inhibits the production of IL-6 by DCs. Azithromycin increases IL-10 and CAM decreases IL-2 productions significantly, when naive T cells derived from spleen are co-cultured with DCs treated in advance with LPS and these macrolides. Azithromycin selectively inhibits fluid-phase endocytosis of horseradish peroxidase and lucifer yellow in J774 mouse macrophages. Azithromycin delays sequestration of receptor-bound transferrin and peroxidase-anti-peroxidase immune complexes into cell-surface endocytic pits and vesicles. Azithromycin down-regulates cell surface transferrin receptors, but not Fc gamma receptors, by causing a major delay in the accessibility of internalized transferrin receptors to the recycling route, without slowing down subsequent efflux, resulting in redistribution of the surface pool to an intracellular pool. Azithromycin inserts into the DOPC lipid bilayer, so as to decrease its cohesion and to facilitate the merging of DPPC into the DOPC fluid matrix.
Cell Research	THP-1 cells (106 cells in 1 mL RPMI medium, without antibiotics, growth factors or serum are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 µL of the test compound is added followed by 50 µL of LPS (final concentration of 10 µg/mL). After 24h (37°C and 5% CO2) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm

Page 1 of 2 www.targetmol.com

Solubility Information

Solubility	DMSO: 18.33 mg/mL (24.47 mM),Sonication is recommended.	
	Ethanol: 74.9 mg/mL (100 mM), Sonication is recommended.	
	(< 1 mg/ml refers to the product slightly soluble or insoluble)	

Preparing Stock Solutions

	1mg	5mg	10mg	
1 mM	1.3351 mL	6.6757 mL	13.3515 mL	
5 mM	0.267 mL	1.3351 mL	2.6703 mL	
10 mM	0.1335 mL	0.6676 mL	1.3351 mL	
50 mM	0.0267 mL	0.1335 mL	0.267 mL	

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Cigana C, et al. P Biochem Biophys Res Commun, 2006, 350(4), 977-982.

Nicholson M W, Huang C Y, Wang J Y, et al. Cardio-and Neurotoxicity of Selected Anti-COVID-19 Drugs.

Pharmaceuticals. 2022, 15(6): 765

Xu K K, Huang Y K, Liu X, et al. Organotypic Culture of Mouse Meibomian Gland: A Novel Model to Study Meibomian Gland Dysfunction In Vitro. Investigative Ophthalmology & Visual Science. 2020, 61(4): 30-30 Sugiyama K, et al. Clin Exp Immunol, 2007, 147(3), 540-546.

Tyteca D, et al. Exp Cell Res, 2002, 281(1), 86-100.

Fan Y, Li M, Ma K, et al. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway. Cancer biology & therapy. 2019, 20(5): 617-632.

Li H, Li J, Li J, et al.Carrimycin inhibits coronavirus replication by decreasing the efficiency of programmed-1 ribosomal frameshifting through directly binding to the RNA pseudoknot of viral frameshift-stimulatory element. Acta Pharmaceutica Sinica B.2024

Fa N, et al. Biochim Biophys Acta, 2007, 1768(7), 1830-1838.

Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18.

Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853. Fan Y, Li M, Ma K, et al. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway[J]. Cancer biology & therapy. 2019, 20(5): 617-632.

Xu K K, Huang Y K, Liu X, et al. Organotypic Culture of Mouse Meibomian Gland: A Novel Model to Study Meibomian Gland Dysfunction In Vitro[J]. Investigative Ophthalmology & Visual Science. 2020, 61(4): 30-30.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com